A liposarcoma is a type of cancer that starts in fat cells. It's usually a large, soft lump under the skin, but it's malignant, meaning it can grow and spread. It needs to be treated with surgery.
Every report comes from a Lived member, sent anonymously.
Have you tried Radiation Therapy for Liposarcoma?
Liposarcoma is a cancer that starts in fat cells within the body's soft tissues. It belongs to the soft tissue sarcomas, a group of rare cancers that arise in fat, muscle, nerves and other connecting tissues, and it is the most common type in that group. It usually appears as a deep lump in an arm or leg, most often the thigh, or as a mass in the retroperitoneum, the space at the back of the abdomen where a tumor can grow large before it causes any symptoms. Liposarcoma is a family of subtypes that behave very differently, so the subtype matters almost as much as the diagnosis itself. Well-differentiated liposarcoma is the most common and grows slowly. It does not spread to distant organs, but it can grow back after surgery; in an arm or leg it is often called an atypical lipomatous tumor. Dedifferentiated liposarcoma usually develops within a well-differentiated tumor and is more aggressive. Myxoid liposarcoma, usually found in the limbs, tends to respond better to chemotherapy and radiation than other types. Pleomorphic liposarcoma is the least common and most aggressive, with the highest chance of spreading. Liposarcoma is different from a lipoma, the common harmless fatty lump under the skin. Lipomas are usually soft and easy to move with the fingers, while liposarcomas tend to be firmer, deeper and fixed to the tissue beneath. A lipoma does not turn into a liposarcoma.
In most people, no specific reason for liposarcoma is found. It begins when fat cells acquire changes in their genes that let them grow without normal control. Some of these changes are typical of a subtype: well-differentiated and dedifferentiated tumors carry extra copies of a gene called MDM2, and myxoid tumors carry a particular gene fusion. These findings help identify the subtype; they do not explain why the cancer started in a given person. Liposarcoma is most often diagnosed between about 50 and 65, is somewhat more common in men and is very rare in children. For soft tissue sarcomas in general, earlier radiation therapy, certain inherited cancer syndromes, long-standing damage to the lymphatic system and long-term exposure to some chemicals, such as vinyl chloride used in making plastics, raise the risk. Most people with liposarcoma have none of these. A lump is sometimes first noticed after an injury, but the injury is not thought to cause it; it usually just draws attention to the area.
Assessment usually begins with imaging. For a lump in an arm or leg, an ultrasound may come first, followed by MRI. For a mass in the abdomen, CT or MRI shows its size, how much of it is fat and how it sits against nearby organs and blood vessels. Features such as a large size, thick strands running through the fat or a solid area that is not fatty make liposarcoma more likely than a lipoma, but imaging alone cannot always tell the two apart. A biopsy confirms the diagnosis and the subtype. Guidelines prefer a core needle biopsy guided by imaging, which removes thin strips of tissue through a needle, over an open surgical biopsy. Because the subtypes can be hard to distinguish, and a sample can miss a more aggressive area within a larger tumor, the tissue should be reviewed by a pathologist experienced in sarcoma. Testing for extra copies of MDM2 helps confirm well-differentiated and dedifferentiated liposarcoma, and genetic sequencing of the tumor may add detail. For a dedifferentiated tumor, the pathologist also assigns a grade (2 or 3), and grade 3 tumors are more likely to spread. For some retroperitoneal tumors whose appearance on imaging is typical of well-differentiated liposarcoma, an expert team may go straight to surgery without a biopsy.
Treatment depends on the subtype, the tumor's size and location, and whether it has spread. Because liposarcoma is uncommon, planning by a sarcoma team matters: a surgeon, medical oncologist, radiation oncologist, radiologist and pathologist who all have sarcoma experience. For tumors in the back of the abdomen, outcomes are better at centers that treat many of these cancers. For a tumor that has not spread, surgery to remove it completely is the main treatment and the only one that can cure it. Surgeons aim to remove a rim of healthy tissue around the tumor while preserving function. For an atypical lipomatous tumor deep in a limb, a less extensive operation is often acceptable because this type does not spread. Retroperitoneal tumors can press against or involve several organs and major blood vessels, which makes the operation larger and riskier and sometimes makes complete removal impossible. Radiation is used in selected cases, usually before surgery, to shrink a tumor or lower the chance that it grows back in the same place. Myxoid liposarcoma is particularly sensitive to it. For retroperitoneal tumors the evidence is mixed: a large trial found no overall benefit, but later analyses suggest that people with well-differentiated or lower-grade dedifferentiated tumors may have fewer recurrences in the abdomen. It has not been shown to help people live longer, and the decision is best made by an experienced team. Chemotherapy is mainly used when the cancer cannot be removed, has come back or has spread, and sometimes before surgery to shrink a tumor. The usual first choice is doxorubicin, an anthracycline chemotherapy drug, alone or combined with ifosfamide. The combination shrinks tumors more often but causes more side effects, particularly low white blood cell counts with fever. Response depends on subtype: myxoid tumors respond more often, while well-differentiated and dedifferentiated tumors are relatively resistant. If the cancer grows after doxorubicin, two drugs given by IV infusion are approved specifically for liposarcoma. Eribulin (Halaven) blocks cancer cells from dividing. In a trial of people with advanced liposarcoma who had already had chemotherapy, median survival was about 15.6 months with eribulin compared with 8.4 months with dacarbazine, an older chemotherapy, although serious side effects were more common. Trabectedin (Yondelis) interferes with how cancer cells use and repair their DNA; it delayed tumor growth compared with dacarbazine and appears to work best in myxoid liposarcoma. At this stage, treatment aims to control the cancer and its symptoms rather than cure it. Clinical trials are testing drugs aimed at the MDM2 and CDK4 genes in well-differentiated and dedifferentiated tumors, immunotherapy, and engineered immune cell therapies for myxoid liposarcoma. Asking about trials is reasonable at any stage.
The outlook varies widely with the subtype, the grade, the tumor's size and location, and whether it can be removed completely. An atypical lipomatous tumor in a limb does not spread to other organs, although it can return in the same place. Dedifferentiated and pleomorphic tumors are more likely to spread to distant sites, and this risk shapes how treatment and follow-up are planned. For tumors in the back of the abdomen, the main long-term problem is regrowth in the same area, even after a successful operation. Some people need more than one operation, or move on to other treatments, over the years. A large abdominal operation can also mean a long recovery before everyday activities return to normal. After treatment, follow-up continues on a regular schedule, with physical exams and imaging such as CT or MRI to look for regrowth or spread. When the cancer is advanced, care becomes a series of decisions about controlling growth, managing symptoms and balancing side effects, and many people use more than one treatment in sequence. Support from the sarcoma team, rehabilitation services and palliative care, which focuses on comfort and quality of life alongside cancer treatment, can make these stages more manageable.
See a doctor about a lump that is getting bigger, feels deep or firm, or comes with pain, swelling, weakness or limited movement in an arm or leg. A lump that has stayed the same size for years is much less concerning than one that is growing. Also arrange an evaluation for swelling or a sense of fullness in the abdomen, feeling full soon after eating, lasting changes in bowel habits or appetite, or weight loss you cannot explain. After treatment, contact your sarcoma team about a new lump near the treated area, an abdomen that is gradually enlarging or new pain, rather than waiting for the next scheduled visit. During chemotherapy, a temperature of 100.4°F (38°C) or higher needs a call to your care team right away, even at night, because chemotherapy can lower the white blood cells that fight infection.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Liposarcoma is like, what's helped you, or ask the community a question.